Combinations of dominant-negative class II transactivator, p300 or CDK9 proteins block the expression of MHC II genes

International Immunology

Volumn 13, Issue 7, 2001, Pages 951-958

  Kanazawa, S ^a   Matija Peterlin, B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Class II transactivator; CREB binding protein; Dominant negative protein; Enhanced green fluorescent protein; MHC II; Positive transcription elongation factor b

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIN DEPENDENT KINASE; ELONGATION FACTOR; GREEN FLUORESCENT PROTEIN; HISTONE ACETYLTRANSFERASE; HLA DP ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN; HYBRID PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MUTANT PROTEIN; PROTEIN P300; SUPERANTIGEN; TRANSACTIVATOR PROTEIN;

ANIMAL CELL; ARTICLE; AUTOIMMUNE DISEASE; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; EPITHELIUM CELL; GENE EXPRESSION; GENE THERAPY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REGULATORY MECHANISM; T LYMPHOCYTE ACTIVATION;

EID: 0034923295     PISSN: 09538178     EISSN: None     Source Type: Journal    
DOI: 10.1093/intimm/13.7.951     Document Type: Article

References (30)

1. Regulation of MHC class II genes: Lessons from a disease
2. Genetic evidence for a new type of major histocompatibility complex class II combined immunodeficiency characterized by a dyscoordinate regulation of HLA-D alpha and beta chains
3. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome)
4. A defect in the nuclear translocation of CIITA causes a form of type II bare lymphocyte syndrome
5. The MHC class II transactivator (CIITA) requires conserved leucine charged domains for interactions with the conserved W box promoter element
6. Mouse class II transactivator: cDNA sequence and amino acid comparison with the human class II transactivator
7. Complex architecture of major histocompatibility complex class II promoters: Reiterated motifs and conserved protein-protein interactions
8. Regulation of transcription of MHC class II genes
9. The class II transactivator CIITA is a transcriptional integrator
10. CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex
11. CREB regulates MHC class II expression in a CIITA-dependent manner
12. Transcriptional scaffold: CIITA interacts with NFY, RFX, and CREB to cause stereospecific regulation of the class II major histocompatibility complex promoter
13. CIITA leucine-rich repeats control nuclear localization, in vivo recruitment to the major histocompatibility complex (MHC) class II enhanceosome, and MHC class II gene transactivation
14. The class II trans-activator CIITA interacts with the TBP-associated factor TAFII32
15. Interactions between the class II transactivator and CREB binding protein increase transcription of major histocompatibility complex class II genes
16. Involvement of CREB binding protein in expression of major histocompatibility complex class II genes via interaction with the class II transactivator
17. Transactivation by CIITA, the type II bare lymphocyte syndrome-associated factor, requires participation of multiple regions of the TATA box binding protein
18. Tat competes with CIITA for the binding to P-TEFb and blocks the expression of MHC class II genes in HIV infection
19. Cyclin K functions as a CDK9 regulatory subunit and participates in RNA polymerase II transcription
20. Identification of multiple cyclin subunits of human P-TEFb
21. Activation and transdominant suppression of MHC class II and HLA-DMB promoters by a series of C-terminal class II transactivator deletion mutants
22. Importance of acidic, proline/serine/threonine-rich, and GTP-binding regions in the major histocompatibility complex class II transactivator: Generation of transdominant-negative mutants
23. Efficient repression of endogenous major histocompatibility complex class II expression through dominant negative CIITA mutants isolated by a functional selection strategy
24. Suppression of MHC class II expression by human class II trans-activator constructs lacking the N-terminal domain
25. Human MHC class II gene transcription directed by the carboxyl terminus of CIITA, one of the defective genes in type II MHC combined immune deficiency
26. Inhibition of human immunodeficiency virus Rev and human T-cell leukemia virus Rex function, but not Mason-Pfizer monkey virus constitutive transport element activity, by a mutant human nucleoporin targeted to Crm1
27. Binding and cooperative interactions between two B cell-specific transcriptional coactivators
28. Recruitment of p300/CBP in p53-dependent signal pathways
29. Class II transactivator (CIITA) is sufficient for the inducible expression of major histocompatibility complex class II genes
30. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA